Jacc: Cardiooncology最新文献

{"title":"Vascular Complications of Atrial Fibrillation in Patients With Cancer","authors":"Lorenzo Gervaso MD, PhD , Daniela Cardinale MD, PhD , Nicola Fazio MD, PhD","doi":"10.1016/j.jaccao.2025.01.003","DOIUrl":"10.1016/j.jaccao.2025.01.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 2","pages":"Pages 168-170"},"PeriodicalIF":12.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy","authors":"Shuang Yang MS ,&nbsp;Xiwei Lou MS ,&nbsp;Mustafa M. Ahmed MD ,&nbsp;Stephen E. Kimmel MD ,&nbsp;Karen C. Daily DO ,&nbsp;Thomas J. George MD ,&nbsp;Carl J. Pepine MD ,&nbsp;Jiang Bian PhD ,&nbsp;Dejana Braithwaite PhD, MSc ,&nbsp;Dongyu Zhang PhD ,&nbsp;Yi Guo PhD","doi":"10.1016/j.jaccao.2024.10.012","DOIUrl":"10.1016/j.jaccao.2024.10.012","url":null,"abstract":"<div><h3>Background</h3><div>Prior research suggests that breast cancer patients with a high burden of frailty may face an increased risk of cardiotoxicity.</div></div><div><h3>Objectives</h3><div>This study sought to examine the association between frailty and cardiotoxicity rates in female breast cancer patients receiving adjuvant therapy after surgery.</div></div><div><h3>Methods</h3><div>We analyzed data from the OneFlorida+ clinical research network, focusing on breast cancer patients treated with adjuvant chemotherapy and targeted therapy from 2012 to 2022. Cardiovascular rates during adjuvant treatments were calculated based on pre-existing frailty, measured using the cumulative deficit frailty index (electronic health record frailty index). We employed multivariable Gray’s method to examine the association between frailty with cardiotoxicity.</div></div><div><h3>Results</h3><div>The final cohort included 2,050 patients (mean age 50.6 years), with 415 (20.2%) experiencing nonfatal adverse cardiovascular events after adjuvant therapy. The incidence of adverse cardiovascular events was 17.8% in robust, 23.2% in prefrail, and 29.4% in frail patients. In multivariable analysis, prefrail (adjusted subdistribution HR [sHR]: 1.35; 95% CI: 1.06-1.71; <em>P</em> = 0.015) and frail (adjusted sHR: 1.70; 95% CI: 1.11-2.61; <em>P</em> = 0.015) patients had a higher likelihood of experiencing adverse cardiovascular events compared with robust patients. Among non-Hispanic White and Black patients, prefrail (adjusted sHR: 1.48; 95% CI: 1.04-2.11; <em>P</em> = 0.031; and adjusted sHR: 1.59; 95% CI: 1.06-2.37; <em>P</em> = 0.024, respectively) and frail (adjusted sHR: 1.96; 95% CI: 1.10-3.50; <em>P</em> = 0.022; and adjusted sHR: 2.13; 95% CI: 1.11-4.10; <em>P</em> = 0.023, respectively) patients were more likely to experience adverse cardiovascular events compared with robust patients. No significant differences were observed in other racial/ethnic groups.</div></div><div><h3>Conclusions</h3><div>These findings highlight the need for close monitoring of cardiotoxicity in frail breast cancer patients undergoing adjuvant treatments to improve cardiovascular risk management.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 2","pages":"Pages 110-121"},"PeriodicalIF":12.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143437054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel Potential Blood Biomarkers for Detection of Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors","authors":"Jan M. Leerink MD, PhD ,&nbsp;Elizabeth A.M. Feijen PhD","doi":"10.1016/j.jaccao.2024.11.005","DOIUrl":"10.1016/j.jaccao.2024.11.005","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 68-69"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782008/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity","authors":"Itamar Braga Dias MSc,&nbsp;Alexander H. Maass MD, PhD","doi":"10.1016/j.jaccao.2024.12.002","DOIUrl":"10.1016/j.jaccao.2024.12.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 53-55"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma","authors":"June-Wha Rhee MD ,&nbsp;Raju Pillai MD ,&nbsp;Sitong Chen MPH ,&nbsp;Alysia Bosworth BA ,&nbsp;Artem Oganesyan MD ,&nbsp;Liezl Atencio MD ,&nbsp;Kendall Freeman BS ,&nbsp;Caitlyn Estrada BS ,&nbsp;Tati Guzman BS ,&nbsp;Kara Lukas BS ,&nbsp;Kelly Peng BS ,&nbsp;Brianna Sigala BS ,&nbsp;Aleksi Lukuridze BS ,&nbsp;Lanie Lindenfeld MA ,&nbsp;Faizi Jamal MD ,&nbsp;Pradeep Natarajan MD ,&nbsp;Smita Bhatia MD, MPH ,&nbsp;Alex F. Herrera MD ,&nbsp;Matthew G. Mei MD ,&nbsp;Ryotaro Nakamura MD ,&nbsp;Saro H. Armenian DO, MPH","doi":"10.1016/j.jaccao.2024.10.006","DOIUrl":"10.1016/j.jaccao.2024.10.006","url":null,"abstract":"<div><h3>Background</h3><div>Patients with lymphoma are at high risk for developing heart failure (HF) after autologous hematopoietic cell transplantation (HCT). More accurate risk determination pre-HCT may facilitate screening and prevention of HF.</div></div><div><h3>Objectives</h3><div>The aim of this study was to examine the association between clonal hematopoiesis of indeterminate potential (CHIP) and the risk for HF after HCT for lymphoma.</div></div><div><h3>Methods</h3><div>This was a retrospective cohort study of 861 patients who underwent autologous HCT for lymphoma between 2010 and 2016 at City of Hope Comprehensive Cancer Center. Targeted DNA sequencing was performed to determine the presence of CHIP (variant allele frequency ≥ 2%). The primary outcome of interest was the 5-year cumulative incidence of de novo HF. Other outcomes of interest included overall and cause-specific mortality.</div></div><div><h3>Results</h3><div>Overall, 186 patients (21.7% of the cohort) had at least 1 CHIP variant, and 59 (6.9%) had ≥2 variants. <em>DNMT3A</em>, <em>PPM1D</em>, and <em>TET2</em> were the most frequently mutated genes. The 5-year incidence of HF was significantly higher in patients with CHIP compared with those without CHIP (13.8% vs 4.7%; <em>P</em> &lt; 0.001; sub-distribution hazard ratio [sHR]: 2.48; 95% CI: 1.32-4.68); the HF incidence increased by variant allele frequency: 0-2% (4.7%), 2-10% (11.7%), and &gt;10% (18.5%), <em>P</em> &lt; 0.001. Patients with CHIP had significantly worse overall survival after HCT, compared with those without (63.4% vs 80.3%; <em>P</em> &lt; 0.001), due primarily to the higher risk for nonrelapse mortality (subdistribution HR: 5.37; 95% CI: 2.34-12.35).</div></div><div><h3>Conclusions</h3><div>CHIP was highly prevalent and associated with risk for HF and nonrelapse mortality after HCT. These findings highlight the role of CHIP as a novel biomarker and potential target for intervention to improve outcomes after autologous HCT.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 20-33"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardio-Oncology and Our Community","authors":"Bonnie Ky MD, MSCE, FACC (Editor-in-Chief, JACC: CardioOncology)","doi":"10.1016/j.jaccao.2024.12.003","DOIUrl":"10.1016/j.jaccao.2024.12.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Page 82"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Biomarkers","authors":"Sabahat Bokhari MD,&nbsp;Ruchika Bhargav DO","doi":"10.1016/j.jaccao.2024.11.006","DOIUrl":"10.1016/j.jaccao.2024.11.006","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 79-81"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant Administration of Dantrolene is Sufficient to Protect Against Doxorubicin-Induced Cardiomyopathy","authors":"Yoshihide Nakamura MD, PhD ,&nbsp;Takeshi Yamamoto MD, PhD ,&nbsp;Shigeki Kobayashi MD, PhD ,&nbsp;Takeshi Suetomi MD, PhD ,&nbsp;Hitoshi Uchinoumi MD, PhD ,&nbsp;Tetsuro Oda MD, PhD ,&nbsp;Motoaki Sano MD, PhD ,&nbsp;Masafumi Yano MD, PhD","doi":"10.1016/j.jaccao.2024.10.011","DOIUrl":"10.1016/j.jaccao.2024.10.011","url":null,"abstract":"<div><h3>Background</h3><div>Doxorubicin (DOX), a commonly used anticancer agent, can result in cardiac dysfunction, presenting a significant clinical challenge. DOX has been shown to induces Ca²⁺ leakage via the ryanodine receptor 2 (RYR2) of the sarcoplasmic reticulum, increasing Ca²⁺ levels in the cytoplasm.</div></div><div><h3>Objectives</h3><div>This study investigated whether stabilizing RYR2 could suppress DOX-induced cardiomyopathy (DIC) and identified the optimal duration of dantrolene treatment as a pharmacological method.</div></div><div><h3>Methods</h3><div>We investigated the effects of RYR2 stabilization on DOX cardiotoxicity using in vivo and in vitro experiments.</div></div><div><h3>Results</h3><div>DOX administration caused calmodulin dissociation, marked Ca²⁺ leakage from RYR2, and increased oxidative stress in isolated cardiomyocytes. Stabilizing the RYR2 tetramer—either pharmacologically with dantrolene or genetically via RYR2 V3599K mutation, which enhances calmodulin binding affinity—suppressed these effects. In DIC mice models, DOX impaired cardiac function, increased fibrosis and TUNEL-positive cells, reduced GRP78, and elevated lipid peroxide levels, leading to endoplasmic reticulum stress and ferroptosis. Both continuous dantrolene treatment and RYR2 V3599K mutation improved cardiac function. Interestingly, dantrolene administration provided myocardial protection even when terminated 7 days after DOX.</div></div><div><h3>Conclusions</h3><div>Short-term concomitant use of dantrolene offers a promising and clinically feasible strategy to prevent DIC. Given dantrolene’s established clinical safety as a treatment for malignant hyperthermia, these findings suggest potential for repositioning dantrolene in DIC prevention.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 38-52"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Full Issue PDF","authors":"","doi":"10.1016/S2666-0873(24)00444-7","DOIUrl":"10.1016/S2666-0873(24)00444-7","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages I-LXXXVI"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143130212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular Considerations After Cancer Therapy","authors":"Anne Blaes MD, MS ,&nbsp;Anju Nohria MD ,&nbsp;Saro Armenian DO, MPH ,&nbsp;Carmen Bergom MD, PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Ana Barac MD, PhD ,&nbsp;Gabriela Sanchez-Petitto MD ,&nbsp;Sanjal Desai MD ,&nbsp;Leah L. Zullig PhD ,&nbsp;Alicia K. Morgans MD, MPH ,&nbsp;Joerg Herrmann MD, PhD","doi":"10.1016/j.jaccao.2024.06.006","DOIUrl":"10.1016/j.jaccao.2024.06.006","url":null,"abstract":"<div><div>Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy–related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy–related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 1","pages":"Pages 1-19"},"PeriodicalIF":12.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}